GLP-1 drugs exendin-4 and semaglutide reduced brain damage and improved survival in newborn mice after oxygen deprivation injury.
1.5 per 1,000 birthsHypoxic-ischemic encephalopathy affects roughly 1.5 in every 1,000 babies born worldwide
What the researchers found
Both exendin-4 and semaglutide improved outcomes when given right after brain injury in newborn mice. The drugs reduced the size of the damaged brain area, increased survival rates, and improved locomotor function in both short-term and long-term assessments.
The mechanism involved upregulation of the PI3K/AKT signaling pathway (a cell survival pathway) and increased cAMP levels (a molecule that helps cells communicate). The drugs also reduced inflammation after oxygen-glucose deprivation in brain cells.
Why it matters
Hypoxic-ischemic encephalopathy (HIE) happens when a baby's brain does not get enough blood and oxygen during birth. It affects about 1.5 per 1,000 live births worldwide and can cause death or severe brain damage. The only current treatment is cooling the baby's body (therapeutic hypothermia). If GLP-1 drugs could add neuroprotection, it would be a major advance.
The numbers in context
- Incidence of HIE: 1.5 per 1,000 live births globally
- Both drugs improved neuropathology scores, survival, and motor function
- PI3K/AKT pathway upregulated
- cAMP levels increased
- Specific effect sizes not reported in abstract
How the study worked
Researchers surgically induced hypoxic-ischemic brain injury in 10-day-old mice by blocking the middle cerebral artery. They then gave the mice exendin-4 or semaglutide systemically right after the injury. They measured brain damage using tissue staining, tracked survival, and tested movement abilities. They also studied the mechanism in brain cells deprived of oxygen and glucose in the lab.
Who was studied
Post-natal day 10 mice with surgically induced hypoxic-ischemic brain injury
What this study cannot tell us
This was tested in mice, not people. Neonatal mouse brain injury is an imperfect model for human HIE. The drugs were given immediately after injury, which may not reflect realistic clinical timing. No long-term developmental or cognitive outcomes were reported. The leap from preclinical mouse data to neonatal clinical use is enormous.
How to read the evidence
Rated preliminary: promising animal study results, but mouse brain injury is an imperfect model for human birth asphyxia, and the drugs were given immediately after injury.
When this study was published
Published in 2024. This is early-stage preclinical research; human trials have not yet been conducted for this use.
The bigger picture
The only current treatment for birth-related brain injury is body cooling. If GLP-1 drugs could provide additional neuroprotection, it would be a major advance for a condition that kills or severely disables thousands of newborns yearly.
Questions still open
- Can these results be replicated in larger animal models?
- Would GLP-1 drugs add benefit on top of therapeutic hypothermia?
- Is the treatment window realistic for clinical use?
Common questions
Could semaglutide be used for brain injury in babies?
How do GLP-1 drugs protect the brain?
Read the original research
Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
EMBO molecular medicine, 16(6), 1284-1309
Citation
Poupon-Bejuit, Laura; Geard, Amy; Millicheap, Nathan; Rocha-Ferreira, Eridan; Hagberg, Henrik; Thornton, Claire; Rahim, Ahad A. (2024). Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.. EMBO molecular medicine, 16(6), 1284-1309. https://doi.org/10.1038/s44321-024-00079-1